# Single Ascending Dose Study of PRX002 in Healthy Subjects

> **NCT02095171** · PHASE1 · COMPLETED · sponsor: **Prothena Biosciences Limited** · enrollment: 40 (estimated)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** PRX002
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02095171
- **Lead sponsor:** Prothena Biosciences Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-12
- **Final completion:** —
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2015-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02095171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02095171, "Single Ascending Dose Study of PRX002 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02095171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*